Darren M Roberts1, Dwarakanathan Ranganathan2, Steven C Wallis3, Julie M Varghese3, Adrian Kark2, Jeffrey Lipman4, Jason A Roberts5. 1. Burns, Trauma & Critical Care Research Centre, School of Medicine, The University of Queensland, Butterfield Street, Herston, Queensland, Australia Medical School, Australian National University, Acton, ACT, Australia darren.roberts@uq.edu.au. 2. Department of Renal Medicine, Royal Brisbane & Women's Hospital, Butterfield Street, Herston, Queensland, Australia. 3. Burns, Trauma & Critical Care Research Centre, School of Medicine, The University of Queensland, Butterfield Street, Herston, Queensland, Australia. 4. Burns, Trauma & Critical Care Research Centre, School of Medicine, The University of Queensland, Butterfield Street, Herston, Queensland, Australia Department of Intensive Care Medicine, Royal Brisbane & Women's Hospital, Butterfield Street, Herston, Queensland, Australia. 5. Burns, Trauma & Critical Care Research Centre, School of Medicine, The University of Queensland, Butterfield Street, Herston, Queensland, Australia Department of Intensive Care Medicine, Royal Brisbane & Women's Hospital, Butterfield Street, Herston, Queensland, Australia Pharmacy Department, Royal Brisbane & Women's Hospital, Butterfield Street, Herston, Queensland, Australia.
Abstract
UNLABELLED: ♦ BACKGROUND: The standard treatment of peritoneal dialysis (PD)-associated peritonitis (PD-peritonitis) is intraperitoneal (IP) administration of antibiotics. Only limited data on the pharmacokinetics and appropriateness of contemporary dose recommendations of IP cefalothin and cefazolin exist. The aim of this study was to describe the pharmacokinetics of IP cefalothin and cefazolin in patients treated for PD-peritonitis. ♦ METHODS: As per international guidelines, IP cefalothin or cefazolin 15 mg/kg once daily was dosed with gentamicin in a 6-hour dwell to patients with PD-peritonitis during routine care. Serial plasma and PD effluent samples were collected over the first 24 hours of therapy. Antibiotic concentrations were quantified using a validated chromatographic method with pharmacokinetic analysis performed using a non-compartmental approach. ♦ RESULTS: Nineteen patients were included (cefalothin n = 8, cefazolin n = 11). The median bioavailability for both antibiotics exceeded 92%, but other pharmacokinetic parameters varied markedly between antibiotics. Both antibiotics achieved high PD effluent concentrations throughout the antibiotic dwell. Cefazolin had a smaller volume of distribution compared with cefalothin (14 vs 40 L, p = 0.003). The median trough total plasma antibiotic concentration for cefazolin and cefalothin during the dwell differed (plasma 56 vs 13 mg/L, p < 0.0001) despite a similar concentration in PD effluent (37 vs 38 mg/L, p = 0.58). Lower antibiotic concentrations were noted during PD dwells not containing antibiotic, particularly cefalothin, which was frequently undetectable in plasma and PD effluent. The median duration that the unbound antibiotic concentration was above the minimum inhibitory concentration (MIC) was approximately 13% (plasma) and 25% (IP) for cefalothin, and 100% (plasma and IP) for cefazolin, of the dosing interval. ♦ CONCLUSIONS: When IP cefalothin or cefazolin is allowed to dwell for 6 hours, sufficient PD effluent concentrations are present for common pathogens during this time. However, with once-daily IP dosing, in contrast to cefazolin, there is a risk of subtherapeutic plasma and PD effluent cefalothin concentrations, so more frequent dosing may be required.
UNLABELLED: ♦ BACKGROUND: The standard treatment of peritoneal dialysis (PD)-associated peritonitis (PD-peritonitis) is intraperitoneal (IP) administration of antibiotics. Only limited data on the pharmacokinetics and appropriateness of contemporary dose recommendations of IP cefalothin and cefazolin exist. The aim of this study was to describe the pharmacokinetics of IP cefalothin and cefazolin in patients treated for PD-peritonitis. ♦ METHODS: As per international guidelines, IP cefalothin or cefazolin 15 mg/kg once daily was dosed with gentamicin in a 6-hour dwell to patients with PD-peritonitis during routine care. Serial plasma and PD effluent samples were collected over the first 24 hours of therapy. Antibiotic concentrations were quantified using a validated chromatographic method with pharmacokinetic analysis performed using a non-compartmental approach. ♦ RESULTS: Nineteen patients were included (cefalothin n = 8, cefazolin n = 11). The median bioavailability for both antibiotics exceeded 92%, but other pharmacokinetic parameters varied markedly between antibiotics. Both antibiotics achieved high PD effluent concentrations throughout the antibiotic dwell. Cefazolin had a smaller volume of distribution compared with cefalothin (14 vs 40 L, p = 0.003). The median trough total plasma antibiotic concentration for cefazolin and cefalothin during the dwell differed (plasma 56 vs 13 mg/L, p < 0.0001) despite a similar concentration in PD effluent (37 vs 38 mg/L, p = 0.58). Lower antibiotic concentrations were noted during PD dwells not containing antibiotic, particularly cefalothin, which was frequently undetectable in plasma and PD effluent. The median duration that the unbound antibiotic concentration was above the minimum inhibitory concentration (MIC) was approximately 13% (plasma) and 25% (IP) for cefalothin, and 100% (plasma and IP) for cefazolin, of the dosing interval. ♦ CONCLUSIONS: When IP cefalothin or cefazolin is allowed to dwell for 6 hours, sufficient PD effluent concentrations are present for common pathogens during this time. However, with once-daily IP dosing, in contrast to cefazolin, there is a risk of subtherapeutic plasma and PD effluent cefalothin concentrations, so more frequent dosing may be required.
Authors: Philip Kam-Tao Li; Cheuk Chun Szeto; Beth Piraino; Judith Bernardini; Ana E Figueiredo; Amit Gupta; David W Johnson; Ed J Kuijper; Wai-Choong Lye; William Salzer; Franz Schaefer; Dirk G Struijk Journal: Perit Dial Int Date: 2010 Jul-Aug Impact factor: 1.756
Authors: Michael Burke; Carmel M Hawley; Sunil V Badve; Stephen P McDonald; Fiona G Brown; Neil Boudville; Kathryn J Wiggins; Kym M Bannister; David W Johnson Journal: Am J Kidney Dis Date: 2011-05-20 Impact factor: 8.860
Authors: Sridevi Govindarajulu; Carmel Mary Hawley; Stephen P McDonald; Fiona G Brown; Johan B Rosman; Kathryn J Wiggins; Kym M Bannister; David W Johnson Journal: Perit Dial Int Date: 2010-02-26 Impact factor: 1.756
Authors: C Jongmans; A E Muller; P Van Den Broek; B De Melo Cruz De Almeida; C Van Den Berg; J Van Oldenrijk; P K Bos; B C P Koch Journal: Front Pharmacol Date: 2022-06-28 Impact factor: 5.988
Authors: Darren M Roberts; Jacob Sevastos; Jane E Carland; Sophie L Stocker; Tom N Lea-Henry Journal: Clin J Am Soc Nephrol Date: 2018-07-24 Impact factor: 8.237